Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Setanaxib (Primary)
- Indications Cholangitis; Primary biliary cirrhosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Calliditas Therapeutics; GenKyoTex
- 26 Jun 2022 Results of a post hoc analysis assessed quality of life presented at The International Liver Congress 2022
- 15 Nov 2021 Results of post-hoc efficacy analysis presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 18 Jun 2020 According to an Abeona Therapeutics media release, Genkyotex will submit the new data from this study for presentation at major international liver conferences.